The cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway has
emerged as a critical innate immune pathway that, following engagement by DNA, promotes …

Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …

Non-coding RNAs (ncRNAs) are a large family of RNA molecules with no capability in
encoding proteins. However, they participate in developmental and biological processes …

Newly growing evidence highlights the essential role that epitranscriptomic marks play in the
development of many cancers; however, little is known about the role and implications of …

Squamous cell lung cancers (lung squamous cell carcinomas [LUSCs]) are associated with
high mortality and a lack of therapies specific to this disease. Although recurrent molecular …

Immune checkpoint blockade (ICB) immunotherapy is a first-line treatment for selected
cancers, yet the mechanisms of its efficacy remain incompletely understood. Furthermore …

Features of the cancer epigenome distinguish cancers from their respective cell of origin and
establish therapeutic vulnerabilities that can be exploited through pharmacologic inhibition …

KRAS-LKB1 (KL) mutant lung cancers silence STING owing to intrinsic mitochondrial
dysfunction, resulting in T cell exclusion and resistance to programmed cell death (ligand) 1 …

Lineage plasticity, a process whereby cells change their phenotype to take on a different
molecular and/or histologic identity, is a key driver of cancer progression and therapy …

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with the
worst prognosis and few effective therapies. Here we identified MS023, an inhibitor of type I …